National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment
In June 2014, the national experts on diabetes mellitus discussed the opportunities to improve the efficacy and outcomes of diabetes treatment using the strategy of patient-oriented care in diabetes. Insulin degludec (Tresiba?) is a new basal ultra-long-acting insulin analogue with a flat, stable gl...
Main Author: | Gagik Radikovich Galstyan |
---|---|
Format: | Article |
Language: | English |
Published: |
Endocrinology Research Centre
2014-10-01
|
Series: | Сахарный диабет |
Subjects: | |
Online Access: | https://www.dia-endojournals.ru/jour/article/view/6698 |
Similar Items
-
Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
by: Lyudmila Alexandrovna Suplotova, et al.
Published: (2015-12-01) -
Insulin degludec is a new ultra-long-acting insulin analogue
by: Ivan Ivanovich Dedov, et al.
Published: (2014-07-01) -
A review of the efficacy and safety of the finished fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes mellitus
by: A. S. Pogorelova
Published: (2018-07-01) -
Basal insulin analogues in the treatment of diabetes mellitus: What progress have we made?
by: Sanjay Kalra
Published: (2015-01-01) -
Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
by: Monika Russel-Szymczyk, et al.
Published: (2019-12-01)